Aceclofenac/eperisone controlled-release - Navipharm

Drug Profile

Aceclofenac/eperisone controlled-release - Navipharm

Alternative Names: Aceclofenac/eperisone SR; Eperisone controlled-release/aceclofenac; Eperisone SR/aceclofenac; NVP-1203

Latest Information Update: 06 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Navipharm
  • Class Esters; Muscle relaxants; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenylacetates; Piperidines; Propiophenones; Small molecules
  • Mechanism of Action Calcium channel antagonists; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Back pain

Most Recent Events

  • 17 Nov 2017 Navipharm Corporation plans a phase II trial for Back pain in South Korea in January 2018 (NCT03341832)
  • 09 Nov 2014 Preclinical trials in Back pain in South Korea (PO)
  • 09 Nov 2014 Navipharm plans two phase I pharmacokinetics trials for Healthy volunteers in South Korea (NCT02289404 and NCT02289274)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top